Antiplatelet medications remain a cornerstone of therapy for atherosclerotic cardiovascular
and cerebrovascular diseases. In primary prevention (patients with cardiovascular risk …

Coronary artery disease remains the major cause of mortality worldwide. Antiplatelet drugs
such as acetylsalicylic acid and P2Y12 receptor antagonists are cornerstone treatments for …

Antiplatelet therapy with P2Y12 receptor inhibitors (clopidogrel, prasugrel, ticagrelor,
cangrelor) is a cornerstone of medical therapy after percutaneous coronary interventions …

This manuscript aims to critically evaluate the current evidence regarding adverse
cardiovascular effects associated with proton pump inhibitors (PPIs) in patients with …

Background: Ticagrelor is an oral antiplatelet agent commonly used to inhibit P2Y12
receptors that bind to it inversely. It is classified as cyclopentyltriazolopyrimidine (CPTP) …

High platelet reactivity (HPR) is a risk factor for stent thrombosis, a potentially lethal
complication of percutaneous coronary intervention. HPR is also associated with increased …

Impact of mild therapeutic hypothermia on bioavailability of ticagrelor in patients with acute
myocardial infarction after ou Page 1 Address for correspondence: Julia M. Umińska, MD …

Abstract Purpose of Review Identification of a reliable discriminatory test to accurately stratify
patient responses to antiplatelet therapy following coronary revascularization has become …

Aims The risk of ticagrelor‐related bleeding events remains a major clinical concern,
especially in East Asian populations. Previous studies have reported higher ticagrelor …

This study aimed to build a mathematical model describing the pharmacokinetics of
ticagrelor and its active metabolite (AR-C124910XX) in a stable setting with concomitant …